title: Urocortin 2 increases c-Fos expression in serotonergic neurons projecting to the ventricular/periventricular system.
abstract: Serotonin plays an important role in the regulation of anxiety states and physiological responses to aversive stimuli. Intracerebroventricular (i.c.v.) injection of the stress- and anxiety-related neuropeptide urocortin 2 (Ucn 2) increases c-Fos expression in serotonergic neurons in the dorsal (DRD) and caudal (DRC) parts of the dorsal raphe nucleus. These regions contain a subset of serotonergic neurons that projects via the dorsal raphe periventricular tract to periventricular structures, including the subfornical organ and ependymal layer, and to the ventricular system. To determine if Ucn 2 activates ventricle/periventricular-projecting serotonergic neurons in the midbrain raphe complex, we made i.c.v. injections of the retrograde tracer Fluoro-Gold into the lateral ventricle, followed 7 days later by i.c.v. injection of Ucn 2. The DRD at -8.18 mm and the DRC at -8.54 mm and -9.16 mm bregma were analyzed using a combined bright field and immunofluorescence technique. Approximately 40% of the ventricle/periventricular-projecting neurons in the subdivisions sampled were serotonergic. Urocortin 2 increased c-Fos expression in ventricle/periventricular-projecting serotonergic neurons in the DRC and in non-ventricle/periventricular-projecting serotonergic neurons in the DRD and DRC. Of the total population of ventricle/periventricular-projecting serotonergic neurons in the DRC at -8.54 and -9.16 mm bregma, 35% expressed c-Fos following Ucn 2 injections. These data are consistent with previous studies showing that i.c.v. injection of Ucn 2 activates subpopulations of serotonergic neurons restricted to the mid-rostrocaudal DRD and DRC and further demonstrate that these include both subsets of serotonergic neurons that do and do not project to the ventricle/periventricular system.
authors.affiliation: Department of Integrative Physiology and Center for Neuroscience, University of Colorado, Boulder, CO 80309-0354, USA. matthew.hale@colorado.edu
authors.forename: Matthew W
authors.initials: MW
authors.lastname: Hale
authors.forename: Christopher E
authors.initials: CE
authors.lastname: Stamper
authors.forename: Daniel R
authors.initials: DR
authors.lastname: Staub
authors.forename: Christopher A
authors.initials: CA
authors.lastname: Lowry
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D002408:Catheters, Indwelling; D002452:Cell Count; D007150:Immunohistochemistry; D008297:Male; D056325:Neuronal Tract-Tracers; D009475:Neurons, Afferent / Q000187:drug effects* / Q000378:metabolism; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism*; D011903:Raphe Nuclei / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D012701:Serotonin / Q000378:metabolism*; D020542:Third Ventricle / Q000378:metabolism*; D014365:Tryptophan Hydroxylase / Q000378:metabolism; D054832:Urocortins / Q000494:pharmacology*
chemical_list: D056325:Neuronal Tract-Tracers; D016760:Proto-Oncogene Proteins c-fos; D054832:Urocortins; D012701:Serotonin; D014365:Tryptophan Hydroxylase
references.citation: Neurochem Res. 2004 Sep;29(9):1739-47
references.pmid: 15453270
references.citation: Neuroscience. 2005;133(4):983-97
references.pmid: 15916857
references.citation: Brain Res. 1993 Oct 8;624(1-2):188-98
references.pmid: 8252391
references.citation: Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20994-9
references.pmid: 19095802
references.citation: Neurosci Lett. 1997 Jul 11;230(1):57-60
references.pmid: 9259463
references.citation: J Comp Neurol. 1986 Jan 15;243(3):363-80
references.pmid: 2419370
references.citation: Neuropsychopharmacology. 2004 Mar;29(3):450-60
references.pmid: 14872203
references.citation: J Comp Neurol. 2004 Jun 28;474(3):364-78
references.pmid: 15174080
references.citation: Neuroscience. 2006 Aug 25;141(2):1047-1055
references.pmid: 16713119
references.citation: Eur J Pharmacol. 2008 Jan 14;578(2-3):185-93
references.pmid: 17945210
references.citation: Anat Histol Embryol. 2008 Feb;37(1):9-18
references.pmid: 18197894
references.citation: Anat Histol Embryol. 1999 Jul;28(3):193-7
references.pmid: 10458025
references.citation: J Comp Neurol. 1978 Jun 1;179(3):641-67
references.pmid: 565370
references.citation: Brain Res. 2002 Jul 5;943(1):142-50
references.pmid: 12088848
references.citation: J Neurochem. 2005 Jul;94(1):45-56
references.pmid: 15953348
references.citation: J Neurosci. 2003 Feb 1;23(3):1019-25
references.pmid: 12574432
references.citation: Acta Anat (Basel). 1989;134(4):319-21
references.pmid: 2741661
references.citation: Am J Psychiatry. 1997 Dec;154(12):1771-3
references.pmid: 9396964
references.citation: Neuropsychopharmacology. 1998 Jun;18(6):492-502
references.pmid: 9571657
references.citation: Peptides. 2004 Apr;25(4):659-66
references.pmid: 15165722
references.citation: Ann N Y Acad Sci. 2004 Jun;1018:58-64
references.pmid: 15240352
references.citation: J Physiol. 2001 Feb 15;531(Pt 1):131-40
references.pmid: 11179397
references.citation: Neuroscience. 1981;6(4):557-618
references.pmid: 7017455
references.citation: J Pharmacol Exp Ther. 2004 Sep;310(3):1027-34
references.pmid: 15115804
references.citation: Brain Res. 2006 Jan 27;1070(1):77-89
references.pmid: 16403469
references.citation: Nat Genet. 2000 Apr;24(4):410-4
references.pmid: 10742108
references.citation: Neuroscience. 2008 Dec 10;157(4):733-48
references.pmid: 18951955
references.citation: Neurosci Lett. 1977 Aug;5(5):297-302
references.pmid: 19605010
references.citation: J Pharmacol Exp Ther. 2002 Jul;302(1):145-52
references.pmid: 12065711
references.citation: J Comp Neurol. 1998 Sep 14;399(1):61-72
references.pmid: 9725701
references.citation: Brain Res. 2003 Feb 14;963(1-2):57-71
references.pmid: 12560111
references.citation: Nat Med. 2001 May;7(5):605-11
references.pmid: 11329063
references.citation: Ann N Y Acad Sci. 1997 Dec 29;836:158-81
references.pmid: 9616798
references.citation: Neuroscience. 1999;89(4):999-1002
references.pmid: 10362289
references.citation: J Psychiatry Neurosci. 1995 Jul;20(4):271-5
references.pmid: 7544158
references.citation: Pharmacopsychiatry. 1995 Mar;28(2):45-50
references.pmid: 7542785
references.citation: J Comp Neurol. 1997 Aug 11;384(4):556-68
references.pmid: 9259489
references.citation: J Neurosci. 2006 May 17;26(20):5500-10
references.pmid: 16707802
references.citation: J Neurosci. 2001 Apr 15;21(8):2833-41
references.pmid: 11306635
references.citation: Neurosci Lett. 1995 Jun 30;193(2):77-80
references.pmid: 7478163
references.citation: J Neurosci. 2004 Feb 11;24(6):1305-11
references.pmid: 14960601
references.citation: Brain Res. 2005 May 24;1044(2):176-89
references.pmid: 15885216
references.citation: Peptides. 2004 Oct;25(10):1703-9
references.pmid: 15476937
references.citation: Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2843-8
references.pmid: 11226328
references.citation: Curr Opin Pharmacol. 2002 Feb;2(1):23-33
references.pmid: 11786305
references.citation: Biol Psychiatry. 1992 Jan 15;31(2):112-8
references.pmid: 1371076
references.citation: Nat Genet. 2000 Apr;24(4):403-9
references.pmid: 10742107
references.citation: Trends Pharmacol Sci. 2008 Sep;29(9):433-6
references.pmid: 18585794
references.citation: Biol Psychiatry. 1999 Nov 1;46(9):1181-91
references.pmid: 10560024
references.citation: Arch Gen Psychiatry. 2008 Jan;65(1):38-46
references.pmid: 18180427
references.citation: J Comp Neurol. 1981 Nov 1;202(3):335-56
references.pmid: 7298902
references.citation: Biol Psychiatry. 2001 Nov 15;50(10):783-91
references.pmid: 11720697
references.citation: Neuroscience. 2004;129(3):509-19
references.pmid: 15541873
references.citation: Neuropsychopharmacology. 2000 Feb;22(2):148-62
references.pmid: 10649828
references.citation: Cell. 1999 Jun 11;97(6):703-16
references.pmid: 10380923
references.citation: Anat Embryol (Berl). 1983;167(3):311-9
references.pmid: 6354002
references.citation: Science. 2003 Aug 8;301(5634):805-9
references.pmid: 12907793
references.citation: Neuroscience. 1998 Jan;82(2):443-68
references.pmid: 9466453